Who are Botulinum Toxin Type A 900kD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nuceiva, Xeomin, Botox, Myobloc, Salmonella Typhi, Botulinum toxin A 150u.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-type-a-900kd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Botulinum Toxin Type A 900kD — Competitive Intelligence Brief

Botulinum Toxin Type A 900kD (Botulinum Toxin Type A 900kD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; acetylcholine release inhibitor. Area: Neurology; Aesthetics; Ophthalmology.

marketed Neurotoxin; acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Aesthetics; Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

Botulinum Toxin Type A 900kD (Botulinum Toxin Type A 900kD) — Allergan. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botulinum Toxin Type A 900kD TARGET	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Nuceiva	BOTULINUM TOXIN TYPE A	GlaxoSmithKline K.K.	marketed	Acetylcholine Release Inhibitor [EPC]	Synaptosomal-associated protein 25	2019-01-01
Xeomin	INCOBOTULINUMTOXINA	Merz Pharms	marketed	Acetylcholine Release Inhibitor [EPC]		2015-01-01
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Myobloc	RIMABOTULINUMTOXINB	Elan Pharm	marketed	Acetylcholine Release Inhibitor [EPC]		2009-01-01
Salmonella Typhi	Salmonella Typhi	University of Oxford	marketed	Acetylcholine Release Inhibitor [EPC]
Botulinum toxin A 150u	Botulinum toxin A 150u	EvergreenHealth	marketed	Neurotoxin; Acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; acetylcholine release inhibitor class)

Allergan · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Croma-Pharma GmbH · 1 drug in this class
NYU Langone Health · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum Toxin Type A 900kD — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-900kd. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab